Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department()

AIMS: Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. Th...

Full description

Saved in:
Bibliographic Details
Published in:Europace
Main Authors: Simon, Alexander, Niederdoeckl, Jan, Skyllouriotis, Ekaterini, Schuetz, Nikola, Herkner, Harald, Weiser, Christoph, Laggner, Anton N., Domanovits, Hans, Spiel, Alexander O.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2017
Subjects:
Clinical Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400093/
https://ncbi.nlm.nih.gov/pubmed/28175295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euw052
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items